Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates

다국어 초록 (Multilingual Abstract)

HIV-1 gp41 is an envelope protein that plays an essential role in virus entry. The mutationof gp41 affects HIV-1 entry and susceptibility to the fusion inhibitor T-20. Therefore, weanalyzed the natural polymorphism of gp41 of 163 HIV-1 isolates from T-20-naïve Koreansinfected with HIV-1. This study of gp41 polymorphisms showed that insertions in thefourth threonine (74.8%) and L7M substitutions (85.3%) were more frequent in the fusionpeptide motif in Korean HIV-1 isolates compared with those from other countries. MinorT-20 resistance mutations such as L45M (1.2%), N126K (1.2%), and E137K (6.7%) weredetected, but the critical T-20 resistance mutations were not detected in the gp41 HR1 andHR2 regions. In addition, the N42S mutation (12.9%) associated with T-20 hypersusceptibilitywas detected at a high frequency. These results may serve as useful data forstudies considering T-20 for use in the development of a more effective anti-retroviraltreatment in Korea.

참고문헌 (Reference)

1 Johnson VA, "Update of the drug resistance mutations in HIV-1 : fall 2006" 14 : 125-130, 2006

2 Johnson VA, "Update of the drug resistance mutations in HIV-1 : March 2013" 21 : 6-14, 2013

3 Morozov VA, "Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy" 35 : 167-174, 2007

4 Kee MK, "Ten-year trends in HIV prevalence among visitors to public health centers under the National HIV Surveillance System in Korea, 2000 to 2009" 12 : 831-, 2012

5 Aquaro S, "Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment" 58 : 714-722, 2006

6 Teixeira C, "Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy" 26 : 307-311, 2010

7 Greenberg ML, "Resistance to enfuvirtide, the first HIV fusion inhibitor" 54 : 333-340, 2004

8 Gottlieb MS, "Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men : evidence of a new acquired cellular immunodeficiency" 305 : 1425-1431, 1981

9 Kilby JM, "Novel therapies based on mechanisms of HIV-1 cell entry" 348 : 2228-2238, 2003

10 Carmona R, "Natural resistance-associated mutations to Enfuvirtide(T20)and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients" 32 : 248-253, 2005

11 Izumi K, "Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design" 45 : 908-915, 2013

12 Mink M, "Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro" 79 : 12447-12454, 2005

13 Pessoa LS, "Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients" 57 : S197-S201, 2011

14 Kim JY, "Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea" 17 : 1155-1159, 2011

15 Kim GJ, "Estimating the origin and evolution characteristics for Korean HIV type 1 subtype B using Bayesian phylogenetic analysis" 28 : 880-884, 2012

16 Xu L, "Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41" 49 : 1113-1119, 2005

17 Pritsker M, "Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes" 38 : 11359-11371, 1999

18 Lohrengel S, "Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides" 79 : 10237-10246, 2005

19 Hudelson SE, "Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors" 25 : 701-705, 2009

20 Bienvenu B, "A cohort study of enfuvirtide immunological and virological efficacy in clinical practice" 78 : 1312-1317, 2006